GDTC
CytoMed Therapeutics Limited Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.50M
P/E Ratio
—
EPS
$-0.23
Beta
0.07
52W High
$3.68
52W Low
$0.68
50-Day MA
$0.90
200-Day MA
$1.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.
Fundamentals
| Revenue (TTM) | 789,040 |
| Gross Profit (TTM) | 677,740 |
| EBITDA | $-3.56M |
| Operating Margin | -476.10% |
| Return on Equity | -56.20% |
| Return on Assets | -32.50% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $0.33 |
| Price-to-Book | 2.10 |
| Price-to-Sales (TTM) | 13.31 |
| EV/Revenue | 37.33 |
| EV/EBITDA | -4.45 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -15.90% |
| Shares Outstanding | $11.93M |
| Float | $3.52M |
| % Insiders | 70.50% |
| % Institutions | 0.14% |
Historical Volatility
HV 10-Day
101.57%
HV 20-Day
83.96%
HV 30-Day
90.32%
HV 60-Day
91.21%
HV Rank
52.4%
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GDTC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026